Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

Arrowhead Pharmaceuticals' CEO is Chris Anzalone, appointed in Dec 2007, has a tenure of 15.83 years. total yearly compensation is $12.03M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.84% of the company’s shares, worth MX$935.82M. The average tenure of the management team and the board of directors is 6.4 years and 12.9 years respectively.

Key information

Chris Anzalone

Chief executive officer

US$12.0m

Total compensation

CEO salary percentage	7.2%
CEO tenure	15.8yrs
CEO ownership	1.8%
Management average tenure	6.4yrs
Board average tenure	12.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Anzalone's remuneration changed compared to Arrowhead Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

Compensation vs Market: Chris's total compensation ($USD12.03M) is above average for companies of similar size in the MX market ($USD1.61M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Anzalone (54 yo)

15.8yrs

Tenure

US$12,031,969

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Kenneth Myszkowski	Chief Financial Officer	13.7yrs	US$4.74m	0.21% MX$ 107.0m
Patrick O'Brien	COO, General Counsel & Secretary	8.8yrs	US$4.73m	0.39% MX$ 196.2m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$4.32m	0.18% MX$ 89.5m
Tracie Oliver	Chief Commercial Officer	1.3yrs	US$2.97m	0.066% MX$ 33.5m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	no data	no data
Vincent Anzalone	Head of Investor Relations & VP	no data	no data	no data
Howard Lovy	Director of Communications	18.2yrs	no data	no data
Mark Seefeld	Head of Toxicology & VP	no data	no data	no data
Javier San Martin	Chief Medical Officer	3.9yrs	US$658.48k	0.050% MX$ 25.6m
Aaron Tan	Head of Tax	1.8yrs	no data	no data
Nadia Meshkova	VP & Treasurer	1.8yrs	no data	no data

6.4yrs

Average Tenure

57.5yo

Average Age

Experienced Management: ARWR *'s management team is seasoned and experienced (6.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	no data	no data
Douglass Given	Chairman of the Board	12.9yrs	US$472.28k	0.13% MX$ 64.2m
Michael Perry	Independent Lead Director	11.8yrs	US$457.28k	0.086% MX$ 43.6m
William Waddill	Independent Director	5.8yrs	US$467.28k	0.027% MX$ 13.7m
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	no data	no data
Mauro Ferrari	Independent Director	13.2yrs	US$457.28k	0.040% MX$ 20.4m
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	no data	no data
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	no data	no data

12.9yrs

Average Tenure

64yo

Average Age

Experienced Board: ARWR *'s board of directors are seasoned and experienced ( 12.9 years average tenure).

Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Insufficient new directors

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Recent updates

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Insufficient new directors

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Full year 2022 earnings released: US$1.67 loss per share (vs US$1.36 loss in FY 2021)

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age